[Effectiveness of plasmapheresis in adolescent myasthenia gravis treatment]. 2010

Sławomir Kroczka, and Jacek A Pietrzyk, and Małgorzata Steczkowska, and Barbara Skowronek-Bała
Klinika Neurologii Dzieciecej Katedry Neurologii Dzieci i Młodziezy, Kraków. neupedkr@cm-uj.krakow.pl

BACKGROUND Myasthenia gravis (MG) is a disease with autoimmune background. Impaired neuromuscular transmission is caused by blockage of acetylcholine receptors on postsynaptic membrane by circulating specific antibodies. Recognition of myasthenia gravis in children, especially its ocular type, may be difficult due to occurrence of similar clinical symptoms in other diseases like ecephalomyopathies. MG is characterized by variety of clinical symptoms and their alternations during excercise and rest. OBJECTIVE Case report of nearly 18-year-old girl with generalized type of MG. METHODS Before hospitalization the girl had been treated psychiatrically for 6 months due to suspicion of conversion disorders. After performance of clinical test and electro-neurophysiological examinations mysathenia gravis was diagnosed and conservative treatment was instituted. Additionally, on the ground of low effectiveness of the treatment, sterydotherapy and immunosuppressive treatment were instituted without marked clinical improvement. Thymectomy was also low effective. Thymic inflammation was recognised histopathologically. Only after performance of 5 plasmapheresis was significant clinical improvement achieved. CONCLUSIONS Plasmapheresis may be used not only in the treatment of myasthenic crisis but also in the treatment of drug-resistant mysthenia gravis.

UI MeSH Term Description Entries
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D010956 Plasmapheresis Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use. Double Filtration Plasmapheresis,Therapeutic Immunoadsorption,Therapeutic Plasma Adsorption,Therapeutic Plasmapheresis,Adsorption, Therapeutic Plasma,Adsorptions, Therapeutic Plasma,Double Filtration Plasmaphereses,Filtration Plasmapheresis, Double,Immunoadsorption, Therapeutic,Plasma Adsorption, Therapeutic,Plasmaphereses,Plasmapheresis, Double Filtration,Plasmapheresis, Therapeutic,Therapeutic Immunoadsorptions,Therapeutic Plasma Adsorptions,Therapeutic Plasmaphereses
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Sławomir Kroczka, and Jacek A Pietrzyk, and Małgorzata Steczkowska, and Barbara Skowronek-Bała
September 2015, Nihon rinsho. Japanese journal of clinical medicine,
Sławomir Kroczka, and Jacek A Pietrzyk, and Małgorzata Steczkowska, and Barbara Skowronek-Bała
June 1986, Revista clinica espanola,
Sławomir Kroczka, and Jacek A Pietrzyk, and Małgorzata Steczkowska, and Barbara Skowronek-Bała
January 1983, Revista clinica espanola,
Sławomir Kroczka, and Jacek A Pietrzyk, and Małgorzata Steczkowska, and Barbara Skowronek-Bała
April 1983, Wiener klinische Wochenschrift,
Sławomir Kroczka, and Jacek A Pietrzyk, and Małgorzata Steczkowska, and Barbara Skowronek-Bała
January 1981, Medicina,
Sławomir Kroczka, and Jacek A Pietrzyk, and Małgorzata Steczkowska, and Barbara Skowronek-Bała
January 1987, Annals of the New York Academy of Sciences,
Sławomir Kroczka, and Jacek A Pietrzyk, and Małgorzata Steczkowska, and Barbara Skowronek-Bała
January 1982, Progress in clinical and biological research,
Sławomir Kroczka, and Jacek A Pietrzyk, and Małgorzata Steczkowska, and Barbara Skowronek-Bała
March 1986, Medicina clinica,
Sławomir Kroczka, and Jacek A Pietrzyk, and Małgorzata Steczkowska, and Barbara Skowronek-Bała
October 1981, Annals of neurology,
Sławomir Kroczka, and Jacek A Pietrzyk, and Małgorzata Steczkowska, and Barbara Skowronek-Bała
January 1978, Transactions of the American Neurological Association,
Copied contents to your clipboard!